Risk of Reinfection From SARS-CoV-2 – An Update of an Antibody Response Following SARS-CoV-2 Infection and Implications for Immunity: A Living Rapid Review

What is the risk of reinfection from SARS-CoV-2 among adults with prior SARS-CoV-2 Title and abstract screening was completed by a single screener and exclusion decisions confirmed by a second screener. Full-text screening was completed by two reviewers and any conflicts resolved by a third independent reviewer. The JBI Checklist for cohort studies was used as an additional level of screening. Consensus was required for exclusion reasons and any conflicts were resolved by a third independent reviewer.

• Publication year

  2022

• Venue

  Unknown venue

• Publication date

  2022-01-24

• Fields of study

  Medicine

• Identifiers
  DOI 10.23970/ahrqepccovidimmunity2
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa 2021-12-01

  2021cited by this paper
• Risk of reinfection after seroconversion to SARS-CoV-2: A population-based propensity-score matched cohort study

  2021cited by this paper
• SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN)

  2021cited by this paper
• Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: an ecological study

  2021cited by this paper
• The risk of symptomatic reinfection during the second COVID-19 wave in individuals previously exposed to SARS-CoV-2

  2021cited by this paper
• Protection of previous SARS-CoV-2 infection is similar to that of BNT162b2 vaccine protection: A three-month nationwide experience from Israel

  2021cited by this paper
• Reinfection With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Patients Undergoing Serial Laboratory Testing

  2021cited by this paper
• SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy

  2021cited by this paper
• SARS-CoV-2 infection and reinfection in a seroepidemiological workplace cohort in the United States

  2021cited by this paper
• The protective effect of SARS-CoV-2 antibodies in Scottish healthcare workers

  2021cited by this paper
• Reinfection by the SARS-CoV-2 P.1 variant in blood donors in Manaus, Brazil

  2021cited by this paper
• Rapid Emergence and Epidemiologic Characteristics of the SARS-CoV-2 B.1.526 Variant — New York City, New York, January 1–April 5, 2021

  2021cited by this paper
• Risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reinfection in a University Student Population

  2021cited by this paper
• Assessment of SARS-CoV-2 Reinfection 1 Year After Primary Infection in a Population in Lombardy, Italy

  2021cited by this paper
• Necessity of COVID-19 Vaccination in Previously Infected Individuals: A Retrospective Cohort Study

  2021cited by this paper
• Comprehensive Characterization of COVID-19 Patients with Repeatedly Positive SARS-CoV-2 Tests Using a Large U.S. Electronic Health Record Database

  2021cited by this paper
• Anti-SARS-CoV-2 Antibodies Persist for up to 13 Months and Reduce Risk of Reinfection

  2021cited by this paper
• Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky, May–June 2021

  2021cited by this paper
• Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections

  2021cited by this paper
• Mild SARS-CoV-2 Illness Is Not Associated with Reinfections and Provides Persistent Spike, Nucleocapsid, and Virus-Neutralizing Antibodies

  2021cited by this paper
• Outbreak of SARS-CoV-2 B.1.617.2 (Delta) Variant Infections Among Incarcerated Persons in a Federal Prison — Texas, July–August 2021

  2021cited by this paper
• SARS-CoV-2 seropositivity and subsequent infection risk in healthy young adults: a prospective cohort study

  2021cited by this paper
• Antibodies to SARS-CoV-2 protect against re-infection during outbreaks in care homes, September and October 2020

  2021cited by this paper
• SARS‐CoV‐2 re‐infection risk in Austria

  2021cited by this paper
• Reinfection Rates among Patients who Previously Tested Positive for COVID-19: a Retrospective Cohort Study

  2021cited by this paper
• Association of SARS-CoV-2 Seropositive Antibody Test With Risk of Future Infection

  2021cited by this paper
• Incidence of SARS-CoV-2 infection according to baseline antibody status in staff and residents of 100 Long Term Care Facilities (VIVALDI study)

  2021cited by this paper
• What Is the Antibody Response and Role in Conferring Natural Immunity After SARS-CoV-2 Infection? Rapid, Living Practice Points From the American College of Physicians (Version 1)

  2021cited by this paper
• Antibody Response After SARS-CoV-2 Infection and Implications for Immunity

  2021cited by this paper
• Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study

  2021cited by this paper
• What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2

  2020cited by this paper
• Prior SARS-CoV-2 infection is associated with protection against symptomatic reinfection

  2020cited by this paper
• Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers

  2020cited by this paper
• Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine Trials

  2020cited by this paper
• A systematic review of antibody mediated immunity to coronaviruses: antibody kinetics, correlates of protection, and association of antibody responses with severity of disease

  2020cited by this paper
• Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study

  2020cited by this paper
• Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: A living systematic review and meta-analysis

  2020cited by this paper
• Predictors of severe symptomatic laboratory-confirmed SARS-CoV-2 reinfection

  2020cited by this paper
• PTSD in prison settings: A systematic review and meta-analysis of comorbid mental disorders and problematic behaviours

  2019cited by this paper
• ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions

  2016cited by this paper
• Methods to estimate the between‐study variance and its uncertainty in meta‐analysis†

  2015cited by this paper
• Assessment of a method to detect signals for updating systematic reviews

  2014cited by this paper
• Grading the Strength of a Body of Evidence When Assessing Health Care Interventions for the Effective Health Care Program of the Agency for Healthcare Research and Quality: An Update

  2013cited by this paper
• A surveillance system to assess the need for updating systematic reviews

  2013cited by this paper
• Measuring inconsistency in meta-analyses

  2003cited by this paper
• Quantifying heterogeneity in a meta‐analysis

  2002cited by this paper
• A note on concordance correlation coefficient.

  2000cited by this paper
• A random-effects regression model for meta-analysis.

  1995cited by this paper
• A general parametric approach to the meta-analysis of randomized clinical trials.

  1991cited by this paper
• An introduction to meta-analysis.

  1989cited by this paper

• What Is the Antibody Response and Role in Conferring Natural Immunity After SARS-CoV-2 Infection? Rapid, Living Practice Points From the American College of Physicians (Version 2)

  2022cites this paper
• Major Update 2: Antibody Response and Risk for Reinfection After SARS-CoV-2 Infection—Final Update of a Living, Rapid Review

  2022cites this paper